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delivered all the way to simulated colon. CPT bound to Poly-β-CD-C6 NPs 
exhibited higher cytotoxicity on HT-29 cells compared to equivalent CPT 
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Abstract 
Colorectal cancer (CRC) is currently the third most lethal cancer globally. Chemotherapeutic 
drugs used for CRC are administered as intravenous (iv) infusion due to their low oral 
bioavailability resulting from their unfavorable physicochemical properties. Non-selective 
biodistribution and difficulties of parenteral administration reduce patient compliance and 
treatment efficacy. To develop cyclodextrin (CD) based cationic nanoparticles (NPs) for CRC 
treatment with model drug camptothecin (CPT) that can be administered orally, protecting 
CPT through gastrointestinal tract (GIT), accumulating at mucus layer and providing an 
effective local treatment for the tumor area. NPs using two different amphiphilic CDs were 
prepared and coated with polyethylenimine (PEI) or chitosan (CS) to obtain positively 
charged surface for all formulations. Pre-formulation studies resulted in optimal formulation,  
CPT loaded Poly-β-CD-C6 NPs, with 135 nm diameter and zeta potential of +40 mV. In vitro 
release study was designed to represent gastrointestinal pH and transit time revealing 52% 
of encapsulated CPT successfully delivered all the way to simulated colon. CPT bound to 
Poly-β-CD-C6 NPs exhibited higher cytotoxicity on HT-29 cells compared to equivalent CPT in 
solution. Caco-2 cell permeability studies showed 276% increase in CPT permeability and 
significantly higher mucosal penetration in cationic CD nanoparticle form.  
 












Cancer is one of the most common chronic diseases in the world, characterized by 
the uncontrolled proliferation and spread of cells (Bilensoy, 2010). Cancer is a complex 
process that results in increased activity of cellular oncogene functions and decreased 
activity in tumor suppressor genes. Since cancers can be caused by any of the different cell 
types in the body, they can vary depending on the cell type from which they originate and 
subsequently the formation process and the responses to treatment varies (Jones and 
Baylin, 2007). Colorectal cancers (CRC) develop as polyps, usually on the inner wall of the 
colon epithelium, showing abnormal growth and proliferation as a malignant neoplasm in 
the mucosa of the colon and rectum. Polyp-related tumors that develop and grow in the 
inner colon epithelium tend to metastasize to other organs by invading muscle tissues and 
lymph nodes. Tumor recurrence and distant metastasis tendencies are the two most 
important factors affecting survival in patients with colorectal cancer. Despite diagnostic and 
therapeutic advances, studies are still underway to seek new diagnosis and treatment 
approaches as it is associated with high morbidity and mortality and the lack of an effective 
oral chemotherapy is one of the most important challenges in cancer treatment in the world 
(You et al., 2016). 
Oral drug administration is the most preferred route because of the ease of 
administration especially for chronic patients who receive long-term medication (Date et al., 
2016). It is less stressful and cost effective for the patient since it is painless and self-
administered without any need for a health facility or health professional for each dosing 
(Plapied et al., 2011). Orally administered drugs can be designed to treat gastrointestinal 
tract (GIT) diseases locally or systemically. Despite the advantages provided by oral drug 
administration, there are some physiological barriers that should be overcome from a 
biopharmaceutical point of view. These barriers can be physiological or biochemical barriers 
characteristic of GIT, but also can be caused by physicochemical properties of the drug such 
as solubility or stability. Camptothecin is a typical example of an anticancer molecule with no 
clinical efficacy due to its solubility and stability issues under physiological conditions. 
Camptothecin (CPT) is an antineoplastic agent with topoisomerase I inhibitor activity. 
Topoisomerases are enzymes involved in the vital functions of DNA, such as DNA replication 
and transcription. Due to the pentacyclic alkaloid inherent in its structure, CPT can show 
strong anticancer activity in a broad spectrum of cancers such as metastatic colon cancers, 
small cell lung cancers, ovarian cancers, breast cancers (Zunino et al., 2002). CPT is known to 
have two different forms that are lactone and carboxylate. The ring (E) in the active lactone 
form is opened and converted to the carboxylate form through hydrolysis. The conversion 
between forms is pH dependent and reversible, rapidly changing to the carboxylate form at 
the alkaline or physiological pH, resulting in decreased clinical efficiency and increased 
toxicity. In this context, research is ongoing to develop innovative CPT formulations to 
overcome existing obstacles and to enable clinical use of CPT (Chao et al., 2017; Davis, 2009). 
The lactone form in the CPT structure, which has not transitioned to the carboxylate form, is 
the functional part that is primarily responsible for anticancer activity because only the CPT 
in the lactone form can pass through the cellular membranes and exhibit topoisomerase I 
inhibitory activity. Because of this situation, CPT shows serious stability and activity 
problems in physiological environment, and also shows low bioavailability due to low 
permeability, P-glycoprotein efflux pump system effect and water solubility problem in oral 
administration (Huang et al., 2008). 
Nanoparticle-bound drug delivery has some advantages compared to conventional 
drug delivery systems. Selection of the nanoparticle material type and modification of 
particle size and surface properties not only allow modulation in drug loading and release 
profile but also render targeting ability and better stability at the site of action, subsequently 
resulting in an increase in the therapeutic response and reduction off-target adverse effects 
(Mohanraj and Chen, 2006). It is possible to overcome the GIT-related multiple barriers both 
because the drug delivery system with oral administration of nanoparticulate drug delivery 
systems. The nanoparticles allow the encapsulated drug to be protected from chemical or 
enzymatic degradation and to control the release profile and release site of the active 
ingredient from the drug delivery system. Thus, treatment can become more effective and 
applied dose, dosing frequency and possible side effects can be reduced and as a 
consequence patients compliance can be increased (Luo et al., 2014). 
Cyclodextrins (CD) are natural cyclic oligosaccharide structure obtained by enzymatic 
degradation of starch with glucosyltransferase. The internal cavity of CDs, that have a three-
dimensional morphology described as cone-like, is hydrophobic and the external structure is 
hydrophilic; which allows the formation of water-soluble complexes including drugs which 
exhibit poor water solubility in the apolar cavity of the cyclodextrins (Trapani et al., 2010). 
Thus, with the drug-cyclodextrin inclusion complex formation, complexed drug can be 
protected from enzymatic or hydrolytic effects in physiological environment resulting in 
higher bioavailability due to increased stability and improved solubility (Qiu et al., 2017).  
Amphiphilic CDs are synthesized in order to overcome the limitations of natural 
cyclodextrins in the pharmaceutical field by facial-selective chemical derivatization 
methodologies. Thus, selectively-grafting bonding linear or branched aliphatic chains of 
different lengths and/or structures on either the primary and/or secondary faces of natural 
cyclodextrins (mostly α and β-CD) impart cyclodextrins self-assembling abilities that 
eventually form nanoscale carriers in an organic solvent: water interface spontaneously 
without any need for auxiliary solvent and/or surfactant (Erdogar et al., 2017). They are able 
to encapsulate hydrophobic drugs both in their cavity, between the aliphatic chains lining 
the primary or secondary face and within the matrix structure that several amphiphilic CDs 
form as supramolecular aggregate in the form of a nanoparticle (Bilensoy and Hincal, 2009).  
In this study, amphiphilic cyclodextrin nanocarriers were prepared using non-ionic 6-O-
CAPRO-β-CD, with a negative surface charge in aqueous solutions and the polycationic 
amphiphilic β-CD derivative Poly-β-CD-C6, originally developed for complexation and 
delivery of nucleic acids (Díaz-Moscoso et al., 2008; Díaz-Moscoso et al., 2009; Jiménez 
Blanco et al. 2017).  6-O-CAPRO-β-CD nanoparticles were coated with either positively 
charged polyethyleneimine (PEI) or chitosan (CS) polymers in order to impart a positive 
surface charge to the nanoparticles. Cyclodextrins are used for drug targeting to the colon, 
because they are not absorbed or degraded in the stomach or intestines and deliver the 
guest/encapsulated molecule to the colon to release the active substance in the colon region 
after being dissociated by the colonic microflora. The purpose of this study is to develop a 
new and unique approach for colon drug targeting for localized treatment of colon tumors. 
The amphiphilic cyclodextrin self-assembled nanoparticle material is intended to remain 
intact along the upper segments of the GIT, then dissociated by the colonic microflora, 
facilitating the local release of the chemotherapeutic drug at the colon region and provide 
an effective and safe nanomedicine for oral administration. Camptothecin was incorporated 
as model chemotherapeutic molecule with severe stability and bioavailability problems. 
Material and methods 
Material 
6-O-CAPRO-β-CD (Mw=1813 g/mol) and Poly-β-CD-C6 (Mw=3178.15 g/mol) (Díaz-Moscoso 
et al., 2008) seen in Figure 1. were synthetized, purified and characterized in Institute for 
Chemical Research (CSIC-University of Sevilla, Spain) (Varan et al., 2016).  
 
Figure 1. Schematic representation and physicochemical properties of 6-O-CAPRO-β-CD and Poly-β-CD-C6. 
 
20-(S)-(+)-camptothecin (95 % HPLC powder, MW: 348.35 g/mol), polyethylenimine 
(branched, Mw: 25,000), dialysis cellulose tubing membrane (average flat width 25 mm, 
MWCO: 14,000 Da), gelatin Type B from bovine skin, mucine from porcine stomach (Type II), 
DTPA (diethylenetriaminepentaacetic acid, min 99%, titration) and egg yolk emulsion were 
purchased from Sigma&Aldrich, USA. Chitosan (Protasan UP G-113; Mw: <200 kDa) was 
purchased from Novamatrix, Norway. All other chemicals used were of analytical grade and 
obtained from Sigma&Aldrich. 
Methods 
Preparation of blank and CPT-loaded amphiphilic CD nanoparticles 
All nanoparticles were prepared by nanoprecipitation method as described previously for 
amphiphilic CD nanoparticles (Varan et al., 2017a). Briefly, variable amounts of 6-O-CAPRO-
β-CD or Poly-β-CD-C6 were dissolved in 1 mL of organic solvent (ethanol or acetone) to yield 
a final concentration of 0.05, 0.1, 0.5 % (w/v) as organic phase. This organic phase was 
added dropwise into water phase consisting only of ultrapure water (2 mL) under magnetic 
stirring (30 min) at room temperature. Then the organic solvent was evaporated with rotary 
evaporator at 45 °C to the desired final volume of 2 mL. To prepare CS or PEI coated 6-O-
CAPRO-β-CD nanoparticles, same technique was run in the presence of CS (0.01, 0.025, 0.05 
% (w/v)) or PEI (2.5, 5, 10 % (w/v)) dissolved in the aqueous phase. Pre-formulation studies 
to optimize nanoparticle formulations with desired particle size, surface charge and physical 
stability parameters should be applied as follows; organic phase: aqueous phase ratio 1:2 
(v/v), concentration of amphiphilic cyclodextrin at 0.1 % (w/v), CS (Protasan UP G-113) 
concentration at 0.025% (w/v) and the PEI (polyethyleneimine) concentration at 5 % (w/v). 
To obtain the camptothecin-loaded nanoparticles, CPT (10 % of CD weight) was added and 
dissolved in organic phase and the same technique described previously was employed to 
form drug loaded nanoparticles dispersion spontaneously.  
In vitro Characterization of the Nanoparticles 
Mean Particle Size and Surface Charge  
The mean particle size (nm), polydispersity index (PDI) and zeta potential (mV) of cationic 
amphiphilic CD nanoparticles were determined by dynamic light scattering (DLS) (Malvern 
Zetasizer Nano ZS series, UK) with a disposable capillary cell. All measurements were 
performed at an angle of 173° for particle size and 12.8° for zeta potential. All formulations 
were measured at room temperature and carried out in triplicate. Particle size distribution 
was calculated as mean diameter (nm) ± standard deviation (SD) and PDI. Zeta potential 
(mV) was stated as the average of three subsequent measurements ± SD. 
Determination of drug loading capacity 
The amounts of CPT in the lactone and carboxylate forms in amphiphilic CD nanoparticle 
formulations were measured directly by a validated isocratic HPLC method with a 
fluorescence detector (HP Agilent 1100, Germany). HPLC method was monitored using 435 
and 370 nm (emission and excitation wavelengths), respectively (Warner and Burke, 1997). 
Briefly, after preparation of nanoparticles, separation of precipitated excess CD and 
undissolved or free drug was carried out by centrifugation at 3500 rpm for 15 min. 
Supernatant containing CPT-loaded amphiphilic CD nanoparticle dispersion was lyophilized 
for 24 hours to obtain nanoparticle powder. Lyophilized nanoparticle powder was dissolved 
in a mixture of DCM: DMSO (1:1 v/v) to quantify total nanoparticle bound CPT according to 
the equation stated below. 
Nanoparticle bound drug % = Calculated drug amount (mcg) / Initial drug added to organic 
phase (mcg) x 100 
In vitro CPT release from amphiphilic CD nanoparticles 
In vitro release characteristics of CPT from the nanoparticle formulations were investigated 
in a release medium with gradually changing pH representing the GIT corresponding to the 
actual transit times with dialysis membrane method at 37 °C in a shaking water bath (100 
rpm) under sink conditions. Release experiments were performed by placing 3 mL CPT-
loaded CD nanoparticle formulation in the dialysis membrane. The closed bag was then 
immersed in release medium which provides external sink conditions with pH 1.2 simulated 
gastric fluid (SGF) for a period of (0-2 h), followed by pH 4.5 simulated intestinal fluid (SIF) 
for (2–4 h) and finally in pH 7.4 simulated colonic fluid (SCoF) (4–24 h) at 37 °C gradually to 
mimic physiological conditions that the nanoparticle will encounter once administered 
orally. At the end of each corresponding time point the dialysis membrane bag was 
transferred to the next release medium. 500 µL of sample was taken from dialysis 
membrane at predetermined time points (0.5, 1, 2, 3, 5, 7, 10 and 24 h) and replaced by 
equal volume of fresh release medium at the same temperature. The cumulative percentage 
of total CPT released for each time point was determined by HPLC simultaneously 
quantifying both the active lactone (r2 = 0.9989) and the inactive carboxylate (r2 = 0.9995) 
forms of the drug.  
Stability of CD nanoparticles in simulated gastrointestinal fluids 
Simulated gastrointestinal fluids (SGF, SIF, SCoF) were used to assess the influence of 
gastrointestinal fluids on the physical stability of CD nanoparticles. 1 mL of each CD 
nanoparticle formulation was added to 9 mL gastrointestinal medium and incubated for 2 h 
in case of SGF, 3 h in case of SIF and 8 h in case of SCoF. At the end of time points for each 
simulated medium, mean particle size (nm), PDI and zeta potential (mV) of the CD 
nanoparticles were measured and evaluated in reference with initial measurement before 
the incubation. 
Physical storage stability of CPT loaded CD nanoparticles 
In order to evaluate the short-term physical stability of the formulations, aqueous 
nanoparticle dispersion were stored at 4 °C for 30 days and the mean particle size (nm), PDI 
and zeta potential (mV) were measured at predetermined intervals (0, 1, 7, 14 and 30 days). 
Penetration of CD nanoparticles through artificial mucus layer 
Penetration of CPT loaded amphiphilic CD nanoparticles through an artificial mucus layer 
model was carried out as previously described (Ungaro et al., 2012). In this method artificial 
mucus layer was prepared and then placed on the gelatin layer. For this purpose, firstly, 10% 
(w/v) gelatin dispersion was prepared by heating on magnetic stirrer in 50 mL of ultrapure 
water at 60°C and 1 mL dispersion was placed in each well of the 24-well cell plates. Gelatin 
dispersion was then cooled at room temperature to form the gelatin layer in the 
experimental model. Artificial mucus was prepared by dissolving 250 mg of mucin, 0.295 mg 
diethylenetriaminpentaacetic acid (DTPA), 250 mg NaCl, 110 mg KCl, 250 µL sterile egg yolk 
emulsion and 1 mL RPMI in 50 mL of ultrapure water under magnetic stirring at room 
temperature. 1 mL artificial mucus was added to each well on the gelatin layer in the 24-well 
plates. The preparation of the artificial mucus layer model to which the experiment will be 
performed is completed by the addition of the artificial mucus solution onto the gelatin 
layer. 
In order to examine the penetration of amphiphilic CD nanoparticles, 500 µL of nanoparticle 
dispersion was added onto this artificial mucus model and left for incubation for 24 h at 
room temperature.  After 24 hours, the artificial mucus containing nanoparticles was 
removed from each well. The lower gelatin layer was washed with ultrapure water (2 mL x 6 
replicate) to remove the mucus completely and then heated to 60 °C to make the solid 
gelatin again to liquefy. It was then centrifuged at 6000 rpm for 20 min and the supernatant 
was removed. The amount of CPT both in lactone and in carboxylate form in the supernatant 
was analyzed by the validated HPLC method. Thus, by using the artificial mucus layer model 
experiment, the ability of nanoparticle dispersions, which is added to the mucus mixture on 
the gelatin layer to penetrate firstly through the mucus layer and then reach the gelatin 
layer, was evaluated by determination of the total CPT and stable fraction of the drug that 
can be transported into the gelatin layer. 
In vitro cell culture studies  
Cytotoxicity of blank CD nanoparticles was evaluated against L929 (American Type Culture 
Collection, USA)  mouse fibroblast cell line. L929 cells were grown in Dulbecco's modified 
Eagle’s medium (DMEM) containing 10 % fetal bovine serum (FBS), penicillin (100 units/mL) 
and streptomycin (100 µg/mL) in 25 cm2 flasks. 5000 cells in 100 µL DMEM were then 
seeded into each well of 96-well plates. Then, the cells were incubated for 24 hours in a 5% 
CO2 incubator at 37 °C. At the end of 24 hours, cell culture medium in the wells was replaced 
with fresh medium containing blank CD nanoparticles at different dilution rates (1:16, 1:32, 
1:64 and 1:128). After 48 hours incubation, 25µL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) in PBS medium (5 mg/mL) was added to each well and 
incubated for 4 hours. Then, 200 µL of DMSO was added to each well to dissolve the 
formazan crystals formed. Optical density (OD) was determined with the plate reader at 450 
nm. The cells incubated with DMEM were evaluated as the control. Cell viability (%) was 
calculated according to the following equation; 
Cell viability (%) = (OD of treated wells/OD of untreated cells) × 100.   
The anticancer activity of CPT-loaded and blank amphiphilic CD nanoparticles was 
researched with a cell culture study procedure aimed at comparing the activity of drug 
loaded nanoparticles with equivalent amounts of drug solution in DMSO at 2 different 
concentrations (0.1 µg/mL, 0.5 µg/mL) and incubation for 48 h on the HT-29 human colon 
cancer cell line. HT-29 cells were seeded in 96-well plates at 104 cells/100µL per well and 
incubated for 24 hours to attach the cells in the wells. 
CPT-loaded CD nanoparticle formulations are diluted with DMEM containing 10 % BSA in 
four different concentrations to achieve equivalent concentrations 0.1 µg/mL and 0.5 µg/mL 
camptothecin 100 µL for either CPT solution or nanoparticle (blank and drug loaded). The 
cells were incubated with CPT-loaded and blank nanoparticle formulations and CPT solutions 
for 48 h. 
At determined time points, 10 µL of water soluble tetrazolium salt (WST-1) was added to 
each well and allowed to incubate for 4 h. Then optical density (OD) at 450 nm was 
determined by the cell plate reader (Molecular Devices, USA). Untreated cells, incubated 
with only cell medium, were accepted as control with 100 % cell viability. Cell viability (%) 
was calculated according to the following equation; 
Cell viability (%) = (OD of treated wells/OD of untreated cells) × 100.   
Evaluation of in vitro transport of CPT across Caco-2 cell line  
In vitro transport evaluation of amphiphilic CD nanoparticles was carried out across the 
human adenocarcinoma Caco-2 cell line. Caco-2 cells, which are passage number 5, were 
passaged and counted. Cells were seeded into 12-well polycarbonate membrane filters 
(Thincerts ™, pore diameter 1 μm, area 1.13 cm2) for permeability studies at a density of 
60.000 cells/insert. 500 µL of culture medium for apical part of the wells and 1 mL of culture 
medium for basolateral part were placed into the inserts. Mediums both in the apical and 
basolateral sections were changed every 48 hours for 18-21 days and incubated in an 
incubator at 37 °C and 5% CO2. When a monolayer of Caco-2 cell formed, cell integrity was 
assessed through transepithelial electrical resistance (TEER) measurement before the 
transmembrane permeability experiments. TEER values were measured by EVOM2 Epithelial 
Voltohmmeter (WPI World Precision Instruments, USA). Permeability experiments were 
initiated when TEER values reached at least 300 Ω·cm2 on the 18th day of the cell seeding.  
Both CPT solution and CPT loaded CD nanoparticle formulations were diluted to contain 20 
µg/mL CPT. Hank's balanced salt solution (HBSS) was placed on the apical and basolateral 
compartments and left for about 30 minutes. Subsequently, CPT solution and CPT loaded CD 
nanoparticle formulations were added to the apical region prepared in 0.5 mL HBSS, and 
only 1 mL HBSS was added to the basolateral region. 
Cells were incubated at 37 °C for 4 hours. Samples were taken from the basolateral section 
at the end of the incubation and analyzed by HPLC. All experimental groups were studied in 
triplicate. The apparent permeability coefficients (Papp, cm/s) for each experimental group 
were calculated as according to the following equation; 
Papp=dQ/dt.1/(A.C0)  
Where dQ/dt is the permeability rate, Co is the initial concentration on the apical side and A 
is the surface area of the monolayer.  
Results and Discussion 
In vitro characterization of CPT loaded amphiphilic CD nanoparticle 
Considering the characterization parameters of CPT-loaded nanoparticles; smallest particle 
size (134.6 ± 19.3 nm) and PDI (0.27 ± 0.03) with the highest positive zeta potential value 
(+40.2±0.32 mV) was obtained for Poly-β-CD-C6 nanoparticles. In previous studies with 
similar amphiphilic cyclodextrins, the smallest particle size could be obtained with the Poly-
β-CD-C6 in a similar manner (Varan et al., 2017a).  
Hydrophilic-lipophilic balance (HLB) of the amphiphilic cyclodextrins was previously reported 
to be crucial on the characteristic parameters of the nanoparticles obtained with amphiphilic 
cyclodextrins whose primary face or secondary faces were modified (Memişoğlu et al., 2002; 
Pflueger et al., 2016). Similarly, in our study, HLB values are variable due to the differences in 
the molecular structure of amphiphilic cyclodextrins. HLB was defined by Griffin as the 
equilibrium between the hydrophilic and lipophilic portions of amphiphilic molecules and is 
calculated according to the following equation (Griffin, 1949, 1954).  
HLB = 20 x Mh / M 
According to this equation; Mh is the molecular mass of the hydrophilic portion and M is the 
molecular mass of the whole molecule, giving a result on a scale of 0 to 20. When considered 
in this point of view, the HLB for 6-O-CAPRO-β-CD, whose only primary face was modified 
with 7 hexanoyl groups, was 10.1, and for the Poly-β-CD-C6, both the primary face of which 
was modified with 7 cationic amine groups and the secondary side with 14 hexanoyl groups, 
the HLB value was 15.8. In this context, when using Poly-β-CD-C6, which has a larger HLB, it 
is thought that interfacial tension between the surfaces where nanoparticle formation 
occurs is reduced more effectively than single face modified derivative 6-O-CAPRO-β-CD. As 
a result, it was thought that smaller particles were obtained with a narrower monodispersity 
by nanoprecipitation process. 
In the case of PEI coated nanoparticles, dispersions having a larger particle size, a wide 
particle size distribution with a high polydispersity index were obtained. This is based on the 
suggestion that the viscosity of the aqueous phase during preparation increases as a result 
of the addition of viscous PEI dispersion, thus resulting in larger nanoaggregates obtained 
through the nanoprecipitation method. When this finding is considered together with the 
information available in the literature on the nanoprecipitation method, the increase in the 
viscosity of the aqueous phase is thought to have a negative effect on the solvent diffusion, 
which allows the formation of nanoparticles (Salatin et al., 2017). Therefore, it has been 
evaluated that the nanoparticles show a high polydispersity with large particles due to the 
inability to obtain them in a stable nanoprecipitation conditions. As a result, 6-O-CAPRO-β-
CD nanoparticles could be coated with PEI, however intended parameters could not be 
achieved (Salatin et al., 2017; Tan et al., 2016). 
 
Table 1. Mean particle size, PDI and zeta potential of blank and CPT-loaded CD nanoparticles prepared with 
optimum parameters determined after pre-formulation studies  (Organic solvent is acetone, CD concentration 







Diameter ± SD 
(nm) 
PDI ± SD ZP ± SD (mV) 
6-O-CAPRO-β-CD 
Blank 194 ± 3 0,11 -24 ± 2 
CPT loaded 252 ± 12 0,27 -22 ± 2 
CS-(6-O-CAPRO-β-CD) 
Blank 284 ± 13 0,23 +18 ± 1 
CPT loaded 298 ± 23 0,29 +19 ± 1 
PEI-(6-O-CAPRO-β-CD) 
Blank 205 ± 6 0,30 +22 ± 1 
CPT loaded 273 ± 42 0,39 +22 ± 1 
Poly-β-CD-C6 
Blank 117 ± 9 0,34 + 42 ± 3 




Determination of drug loading capacity 
Encapsulation efficiency (EE), which is one of the crucial characterization parameters for 
drug delivery systems, is the basic parameter for calculating the amount of drug 
encapsulated into nanoparticle for in vitro and in vivo experiments and dose calculations. 
Encapsulation efficiency should be determined reliably in order to evaluate the efficacy of 
the method and to determine the amount of drug carried by the nanoparticles for eventual 
in vivo and clinical studies (Zhang and Feng, 2006).  
Chemical structure of the amphiphilic CD derivative, nanoparticle preparation method, 
affinity of the active substance, hydrophilic/lipophilic balance and physicochemical 
properties of the active substance are known to influence on the efficiency of encapsulation 
in nanoparticle preparation with amphiphilic β-CD derivatives (Memişoğlu et al., 2003). 
Encapsulation efficiencies of nanoparticle formulations are presented in Table 2. The two 
formulations with the highest CPT encapsulation efficiency were CS-6-O-CAPRO-β-CD (36%) 
and Poly-β-CD-C6 (35%). PEI-6-O-CAPRO-β-CD nanoparticles were found to have a lower 
encapsulation efficiency compared to other formulations because of the ineffectiveness of 
the nanoprecipitation method with PEI (p<0,05). In the CS-6-O-CAPRO-β-CD nanoparticles, 
which have the highest encapsulation efficiency, this situtation was interpreted as a second 
drug layer adsorbed onto the surface with the effect of chitosan polymer used as coating 
material so the drug was either encapsulated and/or adsorbed onto nanoparticles. Although 
no coating material was used, relatively high encapsulation efficiency of CPT was achieved 
for Poly-β-CD-C6 nanoparticles.  
The difference between the encapsulation efficiency of the coated 6-O-CAPRO-β-CD and 
uncoated Poly-β-CD-C6 nanoparticles is thought to result from differences in the molecular 
structure of both amphiphilic CDs. 6-O-CAPRO-β-CD was modified at the primary face with 7 
lipophilic groups, while Poly-β-CD-C6 was modified with 7 cationic groups on the primary 
surface and 14 lipophilic groups on the secondary surface (Varan et al., 2017b). Poly-β-CD-C6 
has more hydrophobic chains because it carries twice the number of aliphatic chains than 6-
O-CAPRO-β-CD. Achieving higher encapsulation efficiency with Poly-β-CD-C6 compared to 6-
O-CAPRO-β-CD is explained by its stronger interaction with hydrophobic CPT.  
Considering from another side, it should be mentioned that Poly-β-CD-C6 show also more 
hydrophilic characteristic since the amine-coated primary face is heavily cationic and this 
face can interact with CPT strongly by electrostatic interactions in terms of encapsulation 
process. As a result of comparison, it can be said that the amphiphilic characteristic of Poly-
β-CD-C6 is heavier than that of 6-O-CAPRO-β-CD, and this situation is thought to be very 
decisive in terms of encapsulation efficiency and cause different results among nanoparticle 
formulations. 
 
Table 2. Encapsulation efficiency (%) of amphiphilic CD nanoparticles for CPT (CD amount is 1 mg/mL and initial 
CPT amount is 0.1 mg/mL in all formulations) (n = 3, ± SD). 
Nanoparticle Formulations Encapsulation efficiency % ± SD 
6-O-CAPRO-β-CD 32,13 ± 2,8 
CS-(6-O-CAPRO-β-CD) 36,56 ± 2,4 
PEI-(6-O-CAPRO-β-CD) 21,04 ± 3,3 
Poly-β-CD-C6 35,11 ± 3,2 
 
In vitro release studies of CPT from amphiphilic CD nanoparticles 
In vitro release studies were carried out for 24 hours. In order to simulate the GIT conditions 
in terms of both pH and transition time, in vitro release study was performed for 0-2 hours in 
SGF, 2-5 hours in SIF and then under SCoF conditions until the end of the experiment. The 
aim of the release study is to reveal whether the formulation, are able to preserve the drug 
encapsulated in the stomach and small intestine, and preferentially release it when it 
reaches the colon. Optimum formulation was expected to carry a majority of CPT active 
lactone form to the colon.  
 
Figure 2. Cumulative release profile of CPT from different amphiphilic CD nanoparticles (n = 3, ± SD). 
 
The majority of the drug release occurred in the first 5 hours particularly in SIF for all 
formulations. The slowest release profile belonged to the Poly-β-CD-C6 nanoparticles. The 
cumulative amount of CPT released in SGF and SIF was found as 61% for CS-(6-O-CAPRO- β-
CD), 77% for PEI-(6-O-CAPRO-β-CD) and 48 for Poly-β-CD-C6 as seen in Figure 2. 
It is known that oral formulations should take approximately 5 hours to reach the colon, and 
that the first 2 hours of this time are spent in the stomach and 3 hours in the small intestine 
(Belali et al., 2019). Additionally, drug delivery systems are exposed to a broad pH range that 
tends to increase from the stomach towards the colon (stomach pH 1.2, small intestine pH 
4.5, column pH 7.4) (Fallingborg, 1999).  At the end of the 5th hour PEI-6-O-CAPRO-β-CD and 
CS-6-O-CAPRO-β-CD nanoparticles showed faster release profiles (p>0.05) than Poly-β-CD-C6 
nanoparticles. This faster release profile can be attributed to the burst release of the CPT, 
which is adsorbed to the coating material surface. Additionally, PEI-6-O-CAPRO-β-CD 
nanoparticles released 77% of the CPT before it reached the colon and did not show a 
favorable release profile. Poly-β-CD-C6 nanoparticles released a smaller amount of CPT 
(48%) before the colon medium as compared to the other formulations (p<0.05). As Poly-β-
CD-C6 formulation can deliver the maximum amount of stable CPT to the colon, it was 
considered as the optimal formulation.  
In the literature, there are studies reporting that the release slows down with the increase of 
the particle size of the nanoparticles, and the release speeds up due to the increase of the 
specific surface area with the decrease of the particle size (Mora-Huertas et al., 2010; Varan 
et al., 2017a). However, in this study, cationic Poly-β-CD-C6 with the smallest particle size 
has a slower release profile than the other formulations. This situation is believed to be 
related to other parameters that affect release profiles except particle size. The primary and 
secondary faces of Poly-β-CD-C6 have been modified with aliphatic chains and it has been 
associated with the slowest release despite the small particle size. In this context, the fact 
that the drug molecule showed high affinity for cyclodextrin as a result of the interaction of 
CPT with both the CD cavity and the modifying groups was interpreted as the cause of the 
slow release profile. Varan et al. reported on comparative drug release profiles of another 
lipophilic anticancer drug paclitaxel from Poly-β-CD-C6 amphiphilic CD nanoparticles and 
non-ionic amphiphilic CD nanoparticles with negative surface charge (Varan et al., 2017a). At 
the end of the study, it has been stated that the nanoparticle with smaller particle size 
shows slower paclitaxel release due to the stronger affinity and electrostatic interaction 
between the drug and the cationic CD, supporting our interpretation. 
Stability of CD nanoparticles in simulated gastrointestinal fluids 
One of the primary conditions for development of an effective system for oral drug 
administration is the stability of both the drug carrier system and the encapsulated drug 
during storage and administration. Therefore, nanoparticulate drug delivery systems 
intended to be administered orally should be able to maintain physical stability under 
various conditions of the gastrointestinal tract (Plapied et al., 2011). As explained previously, 
the most important barriers to oral drug administration are the complex physiological 
structure of the gastrointestinal tract and the physiological barriers such as pH, enzymes, 
mucin, salts, and lipids. Critical quality attributes of nanoparticles such as particle size, PDI 
and zeta potential, which were exposed to the GIT mimicking conditions, are given in Figure 
3.  
Characterization parameters of the nanoparticles according to the results of physical stability 
tests in gastrointestinal simulated fluids; PEI-6-O-CAPRO-β-CD nanoparticles showed 
significant changes in SIF and SCoF (p<0.05). Significant change in physicochemical 
characters of the CS-6-O-CAPRO-β-CD nanoparticles was observed only in simulated colonic 
fluid (p<0.05), whereas Poly-β-CD-C6 remained almost unchanged in simulated 
gastrointestinal fluids.  
The mean particle size and PDI of all the formulations displayed a tendency to increase due 
to the challenging environmental conditions (pH change, ions, salt effect etc.) and incubation 
time of simulated gastrointestinal fluids. Additionally nanoparticles other than Poly-β-CD-C6 
formulation may have a tendency to aggregate due to their zeta potential below ±30 mV 
(Honary and Zahir, 2013). It was observed that zeta potentials tend to decrease for all 
formulations treated with simulated fluids compared to initial values. However, zeta 
potential value of the Poly-β-CD-C6 formulation +44.2 mV initially and +39.9 mV in the 
simulated colon fluid at the end of 8 hours was still sufficiently high for a stable colloidal 
system. Similarly, Lazzari et al. evaluated the stability of polymeric nanoparticles in 
gastrointestinal fluids (Lazzari et al., 2012). There was 20 % increase in the particle size of the 
poly-lactic acid (PLA) (-18 mV) nanoparticles due to aggregation after 24 hours incubation, 
but there was no statistical increase in the poly-methylmethacrylate (PMMA) (-38 mV) 
nanoparticles. This has been reported to arise from the higher zeta potentials of PMMA 
nanoparticles compared to PLA nanoparticles.  
Poly-β-CD-C6 nanoparticles can be a physically stable drug delivery system while maintaining 
stability in all simulated gastrointestinal fluids in terms of mean particle size, polydispersity 
index and zeta potential values. Therefore, it was considered that the drug delivery system 
could have a positive effect on the physiological efficacy of camptothecin due to the 
residence time and chemical stability of camptothecin, which can remain, in the 








Figure 3. Particle size, PDI and zeta potential values of the different formulations, which were, exposed to the 
GIT conditions (n = 3, ± SD) (*; p<0.05). 
 
Physical stability of CPT loaded CD nanoparticles 
Short-term stability results performed for 30 days are given in Figure 4. There was no 
significant change in CS-6-O-CAPRO-β-CD and Poly-β-CD-C6 nanoparticles on days 1, 7 and 
14. On the other hand, a significant change (p<0.05) was determined at day 30 for CS-6-O-
CAPRO-β-CD and Poly-β-CD-C6. For the PEI-6-O-CAPRO-β-CD nanoparticles, although no 
statistically significant change, mean particle size, PDI and zeta potential remained 
significantly higher than the other formulations. Additionally, the PEI-6-O-CAPRO-β-CD 
nanoparticles had a polydispersity index of 0.41 by the end of 30 days, due to the low zeta 
potential (+13.4 mV), the aggregation of the particles over time and the particle size 
distribution spread over a wide range.  
It was observed that the mean particle size was 149.8 nm and polydispersity index was 0.274 
at the end of 30 days for Poly-β-CD-C6 nanoparticles and it could maintain lower particle size 
and higher zeta potential values more effectively than the other formulations. Poly-β-CD-C6 
nanoparticles had an initial zeta potential value of  +40.2 mV and was measured as +37.9 mV 
on the 30th day, which is higher than the other two formulations. Thus Poly-β-CD-C6 can be 
recommended as the physically stable formulation among the all CD nanoparticles probably 




Figure 4. Particle size, PDI and zeta potential values of the different formulations for 30 days (n = 3, ± SD) (*; 
p<0.05). 
In vitro evaluation of nanoparticle interaction with mucus 
For oral formulations, it is important to remain stable and prolong the stay in the GIT. Thus, 
the duration of interaction of the nanoparticulate system with gastrointestinal epithelial 
cells and biological membranes can be increased and sufficient time for effective release of 
the encapsulated drug in the delivery system can be provided. One of the most important 
obstacles to the effectiveness of many orally administered drug delivery systems is that they 
are rapidly eliminated physically from the system as a result of gastrointestinal motility (Luo 
et al., 2014). The interaction of nanoparticles with mucin in the gastrointestinal tract may 
prolong the residence time of the drug delivery system in the region. It should then be able 
to penetrate the mucus layer and reach the epithelial cell layer. It is known that 
nanoparticulate drug delivery systems can alter their interaction with mucin by surface 
modifications and/or alteration of surface charge and the mucoadhesive characteristics of 
drug delivery systems can be modified.  
In the literature, it is stated that nanoparticulate drug delivery systems with positively-
charged surface or systems coated with a positively charged polymer interact with mucin 
and mucus layer at a higher rate and as a result of this they can stay in the intestinal lumen 
for a longer time (Borges et al., 2005).  Unal et al. showed that the positively-charged 
nanoparticle formulations increased interaction with mucin (Ünal et al., 2015a). Similarly, in 
another study conducted by Luo et al. for oral chemotherapy, it was reported that mucin 
was negatively charged (approximately -50 mV) due to the sulfhydryl groups contained in it, 
and interaction with mucin could be increased by the cationic particles for the purpose of 
bioadhesion in the preparation of oral formulations (Luo et al., 2014). 
Orally administered nanoparticles are expected to reach the intestinal epithelial cell layer 
after prolonged stay in the intestinal lumen region by interacting with mucin sufficiently. If 
the interaction with mucin is too tight, it becomes difficult for the nanoparticles trapped in 
the mucin to penetrate the mucus layer and then reach the intestinal cell layer. The steps of 
sufficient interaction with the mucin described above and subsequent penetration into the 
mucus layer are two interrelated and sequential processes that should be in an equilibrium 
state (Ungaro et al., 2012).  
According to the study performed in order to evaluate penetration of nanoparticles to 
mucus layer; the highest penetration rate was found to be Poly-β-CD-C6 formulation with a 
penetration rate of 73%. The CS-6-O-CAPRO-β-CD formulation was the second highest 
penetrating formulation with a penetration rate of 65% and PEI-6-O-CAPRO-β-CD 
formulations penetrated the artificial mucus layer by 45%. The strong cationic surface charge 
of the Poly-β-CD-C6 and CS-6-O-CAPRO-β-CD formulations led a strong electrical interaction 
with the mucus resulting in the high penetration of the drug.  
In order to evaluate the penetration of the nanoparticles to the artificial mucus layer, the 
amount of lactone and carboxylate forms of CPT was calculated separately by the validated 
HPLC method to elucidate the amount of the active and inactive forms of the drug which is 
available in the receptor compartment. In terms of proportion of active lactone form, the 
formulation with the highest total penetration rate was observed for Poly-β-CD-C6 as 73%, 
of which 52% was quantified as the active form. 
Penetration enhancing activities of CDs were demonstrated by literature studies and the 
results obtained at the end of the experiment can be supported (Loftsson and Brewster, 
2011). In a study investigating the intestinal permeability increasing effect of CDs 
(Mazzaferro et al., 2012), it was reported that the intestinal permeability of the docetaxel 
increased significantly with the CD nanoparticles in the rat intestinal ex vivo model. Similarly, 
in the study conducted by Unal et al. mucosal penetrations of Polycaprolactone (PCL), 6-O-
CAPRO-β-CD and CS-6-O-CAPRO-β-CD nanoparticle formulations were compared. At the end 
of the study performed in the artificial mucus model, the highest mucosal penetration has 
been obtained in CS-6-O-CAPRO-β-CD, 6-O-CAPRO-β-CD, PCL nanoparticle formulations, 
respectively. This showed that the intestinal permeability can be increased with CD, and that 
the interaction of nanoparticles with mucin, which gained a positive surface charge with CS 
coating, will increase and enables higher mucosal penetration (Ünal et al., 2015a). 
In addition to the surface charge and cyclodextrin effect, the small particle size of the 
nanoparticles is thought to be effective in interaction with mucin and penetration into the 
mucus layer (Bandi et al., 2020). It has been assessed that the high penetration ability of the 
Poly-β-CD-C6 nanoparticle formulation prepared directly from amphiphilic cyclodextrin 
without any coating material having the smallest particle size and highest positive zeta 
potential may result from the described properties.  
In order to develop an orally administered nanoparticulate system, the mucoadhesive 
feature of the nanoparticles and penetration into the mucus is a process that must be 
sequential and balanced with each other. For this reason, it is known that the nanoparticles 
has a mucoadhesive feature in the intestinal lumen and that the interaction with the mucin 
is at a sufficient level and then the penetration of the mucus should occur (Lai et al., 2009).  
 
 
Figure 5. Amount of CPT penetrated through a artificial mucus gelatin layer from different formulations (n = 3, 
± SD) (*; p<0.05).  
 
In vitro cell culture studies  
Cytotoxicity of blank CD nanoparticles against L929 cell line  
Cytotoxicity of blank CD nanoparticles was assessed on the L929 cell line to predict their 
safety before the in vivo studies as recommended by USP (28). Safety studies on the L929 
cell line are used as the standard method to evaluate the safety and cytotoxic effects on 
healthy cells of nanoparticulate systems designed to be applied to humans. In the literature, 
80% cell viability is considered critical limit and the nanoparticle system is considered safe in 
above this treshold (Reul et al., 2011).  
As seen in Figure 6.; Poly-β-CD-C6 nanoparticles caused significant (p<0.05) cell death 
compared to the control only at a 1:16 dilution ratio. Lower concentrations of Poly-β-CD-C6 
nanoparticles were found to be safe as they didn’t cause significant cell death in reference to 
the control (p>0.05) and the cell viability was still over 83%. On the other hand, PEI-6-O-
CAPRO-β-CD nanoparticles reduced to range of 48%-59% at all dilutions. On the L929 cell line 
recommended by American Pharmacopoeia (USP) 28 for the purpose of evaluating the 
safety of polymeric materials that will contact the patient directly or indirectly; CS-6-O-
CAPRO-β-CD nanoparticles at a dilution of 1:16, Poly-β-CD-C6 nanoparticles at a dilution of 
1:32 were considered as safe, and the cell viability was over 80% (Reul et al., 2011). 
According to the findings presented in Figure 6., PEI-6-O-CAPRO-β-CD nanoparticles showed 
a significant cytotoxic effect compared to the control group and other nanoparticle 
formulations applied at the same dilution rate in all dilution rates. In the studies carried out 
in the literature about PEI used as surface coating polymer to give cationic properties to 
nanoparticles prepared, it is mentioned that the toxic effects of PEI can be observed and 
studies for the development of new and safe PEI derivatives are going on (Okon et al., 2014). 
On the contrary, the lack of such toxicity in CS coated 6-O-CAPRO-β-CD nanoparticles reveals 
the cytotoxic effect of the PEI. For this reason, PEI, which we use as cationic coating polymer, 
has been evaluated as the cause of serious cytotoxicity, which is seen as a result of direct 
and high rates of effect of nanoparticles on cells.  
CS-6-O-CAPRO-β-CD and Poly-β-CD-C6 nanoparticles do not cause a severe cell death to be 
considered as toxicity at 1:32 dilution and lower concentrations. It was determined that the 
cell viability was 83%, 110%, 85% at 1:32 dilution and the cell viability tend to be higher at 
lower concentrations of CS-6-O-CAPRO-β-CD and Poly-β-CD-C6 nanoparticles. Interestingly 
the viability of the cells incubated with CS-6-O-CAPRO-β-CD was higher than the control cells 
and this is thought to be the due to the nutritional property and positive effects of chitosan 
for the cells (Gao et al., 2012).  
As a result of evaluating the safety of blank nanoparticle formulations applied at different 
dilution ratios for 24 hours on L929 cell line, two formulations other than PEI-6-O-CAPRO-β-
CD nanoparticles can be used as safe drug delivery systems. It has been interpreted that the 
cytotoxic effect decreased inversely proportional to the dilution ratios the CS-6-O-CAPRO-β-
CD or Poly-β-CD-C6 nanoparticle suspensions are expected to be further diluted in the body 
fluids and the toxicity profile will therefore be reduced and thus it is considered as safe drug 
delivery systems (Bilensoy et al., 2008). Considering the dilution rates of blank nanoparticles 
evaluated on healthy L929 cells, CPT concentrations that they can carry at an optimal 
dilution rate of 1:32 were calculated as follows; CS-6-O-CAPRO-β-CD (0.56 mcg/mL), PEI-6-O-





Figure 6. Cytotoxicity of blank amphiphilic CD nanoparticles on L929 cell line with MTT assay (n = 3, ± SD). 
 
Antiproliferative Effect of CPT loaded CD Nanoparticles against HT-29 cell line  
In order to evaluate the antiproliferative activity of the CPT-loaded and blank nanoparticles, 
efficacy studies were performed in comparison with the equivalent concentration of 
camptothecin solution on the HT-29 human colon cancer cell line. CPT-loaded and blank 
nanoparticle formulations were compared with the equivalent concentration of CPT solution 
for 48 h incubation time and the results are presented in Figure 7.  
In the evaluation of the antiproliferative activities of the nanoparticle formulations, a 48 
hours incubation time was determined by taking into account the 'doubling time' period and 
the in vitro release profiles of the nanoparticles. In the literature, 'doubling time' is stated as 
2-4 days for HT-29 cells (Forgue-Lafitte et al., 1989). This time refers to the proliferation time 
during which the number of cells can double and is important for the significance of the 
results in evaluating the antiproliferative activities of the formulations. 
When considered in terms of in vitro release profiles, amphiphilic CD nanoparticle 
formulations provided a sustained release profile for 24 hours, completing the release of CPT 
from nanoparticles and evaluating its activity by accumulating in the cell with incubation 
period in the evaluation of anticancer efficacy. It is known that CPT, as a topoisomerase I 
inhibitor, shows cytotoxic effect with S-phase inhibitor activity in the cell cycle where DNA 
synthesis takes place (Minelli et al., 2012). Lalloo et al. also indicated that the S-phase, 
where CPT can exhibit anticancer activity by inhibition of DNA synthesis, is a short-term 
phase in the cell cycle, so that the cell death can be increased in the phase associated with 
repeated administration or extended release formulations, with increased exposure time to 
CPT and its analogues (Lalloo et al., 2004). 
Both drug loaded and blank PEI-6-O-CAPRO-β-CD nanoparticles showed serious toxicity on 
cancer cells, but this is thought to be due to the coating polymer PEI rather than the CPT as 
previously observed in L929 cells. Therefore, the HT-29 cyctotoxicity of PEI-6-O-CAPRO-β-CD 
formulation, which was found unsafe on L929 cells, is ignored.  
The other formulations have been found to exhibit higher anticancer activity in comparison 
with the blank formulations and CPT solution at the same time points and concentrations. It 
has been found that cationic Poly-β-CD-C6 nanoparticles showed higher anticancer activity 
compared to CS-6-O-CAPRO-β-CD formulations due to the increased cell intake as result of 
the high cationic property and strong cellular interaction. It has been reported that by Varan 
et al. the interaction of cationic nanoparticles with negatively charged cell membrane is 
higher, and this has been shown to be due to interaction with negatively charged molecules 
in the cell membrane (Varan et al., 2016). Similarly, another study by Verma et al. 
emphasized the importance of the surface properties and zeta potential of the nanomaterial 
in the cellular interaction and intracellular mechanisms of nanomaterials (Verma and 
Stellacci, 2010). It is also known that CDs and self-assembled amphiphilic CD NPs are able to 
remove cholesterol from the cell membrane and negatively alter membrane dynamics, 
permeability and endocytic cell uptake mechanisms. In this context, it is know that 
methylated-β-CD is used as an endocytosis inhibitor (Vercauteren et al., 2010). Therefore, 
CD interaction with cell membrane constituents, cholesterol in particular, is expected to be 
stronger with a more amphiphilic and cationic character. In fact, Varan et al also 
demonstrated that cationic poly-β-CD-C6 nanoparticles are able to extract high amounts of 
cholesterol from MCF-7 breast cancer cells as well as uncoated 6-O-CAPRO- β-CD 
nanoparticles inducing apoptosis through a mitochondrial pathway (Varan et al., 2016). 
Formulations of CS-6-O-CAPRO-β-CD and Poly-β-CD-C6 exhibit higher anticancer activity than 
equivalent concentrations of camptothecin solution throughout the study. This indicates 
that the increased therapeutic effect expected from the nano formulation could be 
achieved. Compared with the drug solution, according to 48 hours data; all nanoparticles at 
a concentration of 0.1 µg/mL and 0.5 µg/mL had significantly higher (p<0.05) anticancer 
activity. Considering cell viability, the most suitable dose dependent profile was obtained 
with Poly-β-CD-C6 nanoparticles and it showed significantly higher anticancer activity at all 
concentrations and time points compared to the drug solution. The results show that by 
encapsulating CPT into amphiphilic CD nanoparticles, higher anticancer activity could be 
achieved than when camptothecin is used as an oral solution. Increased anticancer activity 
depends on the degree of cellular interaction and uptake of the drug delivery system as 
results of the characterization parameters such as surface charge and particle size (He et al., 
2010).  
 
Figure 7. Anticancer activity of CPT-loaded and blank amphiphilic CD nanoparticle formulations and CPT 
solution in DMSO on HT-29 cell line after 48 h of incubation (n = 3, ± SD).  
In vitro transport evaluation of CPT loaded CD nanoparticles across Caco-2 cell line  
The permeability of the oral formulations is a crucial parameter for bioavailability in terms of 
their ability to penetrate the intestinal lumen and act on the tissues and pass into the 
systemic circulation. The ability of the monolayer cell structure formed by the Caco-2 cell 
line on the transwell to mimic the epithelial cell layer in the intestinal lumen depends on the 
robustness of the resulting cell layer and the transepithelial electrical resistance (TEER) .  
Intestinal permeability of free CPT and CPT-loaded into nanoparticles was investigated on 
the Caco-2 cell line. The apparent permeability coefficient (Papp) of free CPT and 
nanoparticulate CPT formulations was found to decrease in the order of CS-(6-O-CAPRO-β-
CD) > Poly-β-CD-C6 > PEI-(6-O-Capro-B-CD) > CPT. The Papp of all nanoparticle formulations 
were significantly different compared to the CPT solution and each other, and significantly 
higher than the CPT solution (p<0.05). 
Papp increased 2.9, 2.76, 2.16 and 1.64 folds for CS-6-O-CAPRO-β-CD, Poly-β-CD-C6, 6-O-
CAPRO-β-CD and PEI-6-O-Capro-B-CD nanoparticles in comparison to the permeability of the 
free drug CPT. It was considered that obtaining the highest apparent permeability coefficient 
in CS-6-O-CAPRO-β-CD nanoparticles was related to increased cellular interaction due to the 
positive charge gained by modification of the nanoparticle surface with CS and increased 
adhesion to the cell and the residence time on the cell. When considered in this context, an 
increase of 2.76 fold comparison to the permeability constant of the free drug CPT was 
observed in the second highest formulation Poly-β-CD-C6, which could provide the increase 
in permeability, and it was accepted as another promising formulation in terms of results. 
On the basis of this increase in drug permeability, it has been contemplated that the average 
particle size of Poly-β-CD-C6 nanoparticles, which is smaller than other formulations, may 
result in increased permeability from the intestinal cell layer.  
Unal et al. investigated the permeabilities of the anionic and cationic CD nanoparticles 
loaded with the CPT from the Caco-2 cell layer, it was reported that a 50% increase in the 
permeability from the Caco-2 cell layer was achieved compared to the anionic form of the 
nanoparticles (Ünal et al., 2015b). Also, Derakhshandeh et al. investigated the effect of 
particle size of nanoparticles on the permeability of the Caco-2 cell layer. For this purpose, 
CPT loaded PLGA nanoparticles with different particle sizes were prepared and their 
permeability was investigated. The results showed that by increasing the particle size 
gradually from 100 nm to 950 nm, the permeability of the CPT loaded PLGA nanoparticles 
from the Caco-2 cell layer decreased (Derakhshandeh et al., 2011). 
It is also known that there is a transition from the active lactone form to the inactive 
carboxylate form of CPT at neutral and basic pHs in physiological environment, and diffusion 
of the inactive form from the biological membranes is slower and lower than the active 
lactone form (Thakral et al., 2012). At pH 7.4, in which permeability studies are carried out, 
the free camptothecin active lactone form is known to gradually hydrolyse into the inactive 
carboxylate form. In this context, Poly-β-CD-C6 formulation, which exhibits a slower release 
than other formulations and diffuses faster and easily through the intestinal cell barrier due 
to its smaller particle size, might provide more stable and effective permeation of 
camptothecin through the intestinal cell layer. When all the information were taken into 
consideration, it was possible to prevent the hydrolysis of camptothecin in an encapsulated 
system from the physiological conditions and to increase its stability by slowing the 
conversion to inactive carboxylate form. Thus, it has been found that camptothecin, which 
can be preserved in its active lactone form, may diffuse more through the intestinal cell layer 
than its inactive form, the carboxylate form (Yue et al., 2011). 
Table 3. Apparent permeability coefficient (Paap) of different CPT loaded CD nanoparticle formulations (n = 3, ± 
SD). 
Formulations Papp (x10
-6 cm/s) ± SD Increase in permeability (%) 
Free CPT 3.12 ± 0.49 - 
CS-(6-O-CAPRO-β-CD) 9.15 ± 1.02 293.2 
PEI-(6-O-CAPRO-β-CD) 5.13 ± 1.27 164,4 
Poly-β-CD-C6 8.64 ± 1.31 276.9 
  
Conclusion and Future Perspectives 
In today's knowledge, pathophysiology related to many diseases have been enlightened to a 
great extent and, accordingly, new forms of treatments have emerged. Drug administration 
by injection reduces the effectiveness of treatment during the procedure due to patient 
compliance, severity and frequency of side effects, and difficulty in administration. 
Therefore, as an alternative to parenteral administration, transdermal, nasal, buccal, 
pulmonary or oral administration methods are being studied. Oral administration is 
preferred among all these alternatives. In terms of ease of application and patient 
compliance, it stands out as the most advantageous way to be used in chronic diseases. 
Orally administered drugs can be designed to treat gastrointestinal tract (GIT) diseases 
locally or to achieve a systemic effect by passing into the bloodstream. In addition to the 
advantages provided by oral drug administration, there are some obstacles that must be 
overcome when evaluated in terms of pharmaceutical science. Today, orally administered 
drugs, which make up the majority of the pharmaceutical market, are growing rapidly in line 
with the increasing demand in parallel with the benefits provided by the patient in practice. 
In line with the demand in question, scientific studies regarding the drug administration by 
the oral route continue increasingly.  
Localized cancer therapy facilitates the delivery of chemo- or immunotherapeutic- drug 
directly to the site of disease in a controlled manner, sparing off-target tissue toxicities. 
Colon specific drug delivery systems are intended for local treatment of colon site specific 
diseases such as ulcerative colitis (UC), irritable bowel disease (IBD) and CRC, or for the 
peptide-protein drugs that are intended to be absorbed at the colon. Various formulation 
approaches have been developed for drug delivery to the colon. These are in principle 
approaches that aim to deliver drugs to the colon region by making use of one or more of 
the physiological properties of the GIT. The fact that different segments of the GIT are in 
different pH ranges, enzymes activity in the GIT and the activities of colonic bacteria present 
in the colon region are the main conditions used in the development of colon targeted drug 
delivery systems.  
The point reached at the end of the our study; it is possible to perform an oral cationic 
amphiphilic CD nanoparticulate drug delivery system for the anticancer treatment of 
colorectal tumors with oral drug delivery systems, which can be used in the treatment of 
cancer rarely, and specifically not applicable to digestive tract tumors. Thus, a 
nanoparticulate drug delivery system has been developed that can be administered orally 
and provides local treatment by delivering the drug it carries to the effect area. For this 
reason, a nanoparticulate drug delivery system, which can be administered orally but which 
acts locally, thus preventing or minimizing the systemic side effects of the drug they contain, 
is aimed at both reducing the side effects and increasing the stability of the drug. In addition, 
due to the submicron sizes of the nanoparticles, it is considered that the drug concentration 
in the region can be increased due to the increased permeability and permeability effect, 
due to the nanoparticle, which can be highly localized in the tumor tissue.  
In order to inspire further studies in the future, the findings of our study, that designed a 
cationic amphiphilic CD nanoparticulate drug delivery system, which is targeted to the colon 
with a passive targeting strategy, can be administered orally, remains stable until the colon, 
releases the active substance it carries as a result of degradation by the colonic microflora, 
can be used. In this context, with the development of new amphiphilic cationic CD 
nanoparticle formulations that can carry active targeting ligands for the colon tumors in the 
future, it is considered that systems that reach the colon with passive targeting and that 
offer a more specific treatment approach focused on the tumor with active targeting in the 
colon. 
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